"Nuclear Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
| Descriptor ID |
D009687
|
| MeSH Number(s) |
D12.776.660
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nuclear Proteins".
Below are MeSH descriptors whose meaning is more specific than "Nuclear Proteins".
This graph shows the total number of publications written about "Nuclear Proteins" by people in this website by year, and whether "Nuclear Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 22 | 14 | 36 |
| 1995 | 29 | 15 | 44 |
| 1996 | 32 | 11 | 43 |
| 1997 | 45 | 20 | 65 |
| 1998 | 49 | 23 | 72 |
| 1999 | 49 | 20 | 69 |
| 2000 | 43 | 21 | 64 |
| 2001 | 40 | 24 | 64 |
| 2002 | 39 | 15 | 54 |
| 2003 | 48 | 34 | 82 |
| 2004 | 52 | 41 | 93 |
| 2005 | 44 | 63 | 107 |
| 2006 | 45 | 28 | 73 |
| 2007 | 43 | 26 | 69 |
| 2008 | 35 | 33 | 68 |
| 2009 | 43 | 29 | 72 |
| 2010 | 45 | 21 | 66 |
| 2011 | 62 | 31 | 93 |
| 2012 | 41 | 30 | 71 |
| 2013 | 51 | 18 | 69 |
| 2014 | 39 | 38 | 77 |
| 2015 | 47 | 20 | 67 |
| 2016 | 40 | 29 | 69 |
| 2017 | 39 | 21 | 60 |
| 2018 | 33 | 22 | 55 |
| 2019 | 23 | 15 | 38 |
| 2020 | 19 | 20 | 39 |
| 2021 | 25 | 8 | 33 |
| 2022 | 7 | 18 | 25 |
| 2023 | 6 | 32 | 38 |
| 2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nuclear Proteins" by people in Profiles.
-
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell. 2024 Apr 08; 42(4):605-622.e11.
-
High Clinical Exome Sequencing Diagnostic Rates and Novel Phenotypic Expansions for Nonisolated Microphthalmia, Anophthalmia, and Coloboma. Invest Ophthalmol Vis Sci. 2024 Mar 05; 65(3):25.
-
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2024 01 17; 30(2):334-343.
-
Epigenetic regulation of asymmetric cell division by the LIBR-BRD4 axis. Nucleic Acids Res. 2024 Jan 11; 52(1):154-165.
-
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 Mar; 38(3):545-556.
-
The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma. Cancer Res. 2023 12 01; 83(23):3846-3860.
-
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes. Cancer Res. 2023 12 01; 83(23):3956-3973.
-
Loss of the methylarginine reader function of SND1 confers resistance to hepatocellular carcinoma. Biochem J. 2023 11 29; 480(22):1805-1816.
-
circ-hnRNPU inhibits NONO-mediated c-Myc transactivation and mRNA stabilization essential for glycosylation and cancer progression. J Exp Clin Cancer Res. 2023 Nov 23; 42(1):313.
-
Enhanced CD19 activity in B cells contributes to immunodeficiency in mice deficient in the ICF syndrome gene Zbtb24. Cell Mol Immunol. 2023 12; 20(12):1487-1498.